Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ADCT Adc Therapeutics SA
- Stocks
- Healthcare
- NYSE: ADCT
Price (delayed)
$3.66
Market cap
$362.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.43
Enterprise value
$290.02M
adc therapeutics is a biotechnology company located in lausanne, vaud, switzerland.
Highlights
Adc Therapeutics's EPS has increased by 48% YoY and by 12% QoQ
The company's net income rose by 34% YoY and by 5% QoQ
Adc Therapeutics's quick ratio has increased by 16% from the previous quarter but it has decreased by 4.2% YoY
Adc Therapeutics's equity has decreased by 23% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of ADCT
Market
Valuations
Earnings
Shares outstanding
99.18M
Market cap
$362.99M
Enterprise value
$290.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.83
Revenue
$75.82M
Gross profit
$70.32M
Operating income
-$125.51M
Net income
-$149.84M
EBIT
-$99.73M
EBITDA
-$96.5M
Free cash flow
-$136.67M
Per share
Balance sheet
Liquidity
EPS
-$1.43
EPS diluted
-$1.43
Free cash flow per share
-$1.27
Book value per share
-$2.4
Revenue per share
$0.71
TBVPS
$2.54
Total assets
$272.54M
Total liabilities
$510.76M
Debt
$121.73M
Equity
-$238.22M
Working capital
$200.2M
Debt to equity
-0.51
Current ratio
4.46
Quick ratio
3.92
Net debt/EBITDA
0.76
Margins
Efficiency
Dividend
EBITDA margin
-127.3%
Gross margin
92.7%
Net margin
-197.6%
Operating margin
-165.5%
Return on assets
-45.6%
Return on equity
N/A
Return on invested capital
-76.5%
Return on capital employed
-46.4%
Return on sales
-131.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADCT stock price
How has the Adc Therapeutics stock price performed over time
Intraday
6.4%
1 week
18.45%
1 month
183.72%
1 year
5.17%
YTD
83.92%
QTD
159.57%
Financial performance
How have Adc Therapeutics's revenue and profit performed over time
Revenue
$75.82M
Gross profit
$70.32M
Operating income
-$125.51M
Net income
-$149.84M
Gross margin
92.7%
Net margin
-197.6%
Adc Therapeutics's net margin has increased by 40% YoY and by 11% QoQ
The company's net income rose by 34% YoY and by 5% QoQ
ADCT's operating margin is up by 24% year-on-year and by 10% since the previous quarter
Adc Therapeutics's operating income has increased by 16% YoY and by 3.9% QoQ
Price vs fundamentals
How does ADCT's price correlate with its fundamentals
Growth
What is Adc Therapeutics's growth rate over time
Valuation
What is Adc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.83
Adc Therapeutics's EPS has increased by 48% YoY and by 12% QoQ
Adc Therapeutics's equity has decreased by 23% YoY and by 18% from the previous quarter
ADCT's price to sales (P/S) is 89% lower than its 5-year quarterly average of 44.6 but 39% higher than its last 4 quarters average of 3.5
The revenue has increased by 10% YoY and by 7% from the previous quarter
Efficiency
How efficient is Adc Therapeutics business performance
Adc Therapeutics's return on sales has increased by 36% YoY and by 13% QoQ
The ROA has grown by 18% YoY and by 2.4% from the previous quarter
The return on invested capital has increased by 12% year-on-year and by 9% since the previous quarter
Dividends
What is ADCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADCT.
Financial health
How did Adc Therapeutics financials performed over time
Adc Therapeutics's total assets is 47% less than its total liabilities
ADCT's current ratio is up by 17% since the previous quarter but it is down by 3.3% year-on-year
Adc Therapeutics's quick ratio has increased by 16% from the previous quarter but it has decreased by 4.2% YoY
Adc Therapeutics's debt is 151% higher than its equity
Adc Therapeutics's equity has decreased by 23% YoY and by 18% from the previous quarter
The debt to equity has grown by 19% YoY and by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.